A
0.829
0.01 (1.10%)
| Penutupan Terdahulu | 0.820 |
| Buka | 0.875 |
| Jumlah Dagangan | 21,362 |
| Purata Dagangan (3B) | 73,710 |
| Modal Pasaran | 5,797,891 |
| Harga / Buku (P/B) | 0.420 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| Margin Operasi (TTM) | -2,514.78% |
| EPS Cair (TTM) | -2.34 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -57.30% |
| Nisbah Semasa (MRQ) | 5.90 |
| Aliran Tunai Operasi (OCF TTM) | -13.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.46 M |
| Pulangan Atas Aset (ROA TTM) | -35.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -59.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Aprea Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
0.6
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.63 |
|
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.90% |
| % Dimiliki oleh Institusi | 40.94% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 7.00 (Wedbush, 744.39%) | Beli |
| Median | 5.50 (563.45%) | |
| Rendah | 4.00 (HC Wainwright & Co., 382.51%) | Beli |
| Purata | 5.50 (563.45%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 0.625 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 10 Feb 2026 | 7.00 (744.39%) | Beli | 0.660 |
| HC Wainwright & Co. | 29 Jan 2026 | 4.00 (382.51%) | Beli | 0.590 |
| 18 Dec 2025 | 5.00 (503.14%) | Beli | 0.910 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |